Pulsed Magnetic Therapy for Neuropathy using Pulsed Electromagnetic Field therapies PEMF have been found to have beneficial and protective neurological effects.  Beside promoting various physiological, psychological and neurological healing mechanisms, PEMF’s turn on body’s ability to regenerate bone, muscle and nerve tissue and reduce inflammation.  It doesn’t just treat the pain, it repairs the cause of the pain. Another area where there is no funding for research since BigPharma counts on sales of pain meds so heavily.

pemf devices and therapy for neuropathy chronic pain relief

See also our bibliography on Magnetic Therapy and General Pain with many more studies on pain than simply those termed neuropathy / neuropathic. We guarantee satisfaction in 90-days or return for refund; no matter why you buy your EarthPulse™; plus better sleep and overall improved quality of life.

Magnetic Therapy Neuropathy – Pulsed Electromagnetic Field Therapy PEMF Bibliography

To read the original source, use Pubmed and search for Title of the citation

Eur J Pain. 2013 Oct;17(9):1347-56. doi: 10.1002/j.1532-2149.2013.00320.x. Epub 2013 Apr 29.
H-coil repetitive transcranial magnetic stimulation for pain relief in patients with diabetic neuropathy.
Onesti E, Gabriele M, Cambieri C, Ceccanti M, Raccah R, Di Stefano G, Biasiotta A, Truini A, Zangen A, Inghilleri M.

Therapeutic effects of 15 Hz pulsed electromagnetic field on diabetic peripheral neuropathy in streptozotocin-treated rats.
Lei T, Jing D, Xie K, Jiang M, Li F, Cai J, Wu X, Tang C, Xu Q, Liu J, Guo W, Shen G, Luo E.
PLoS One. 2013 Apr 18;8(4):e61414. doi: 10.1371/journal.pone.0061414. Print 2013.

one 20 minute application of 10 Hz rTMS study ->> Neurophysiol Clin. 2001 Aug;31(4):247-52.
Interventional neurophysiology for pain control: duration of pain relief following repetitive transcranial magnetic stimulation of the motor cortex.
Lefaucheur JP, Drouot X, Nguyen JP.
Service de physiologie-explorations fonctionnelles, hôpital Henri-Mondor, Inserm U421, faculté de médecine, 94010 Créteil, France.

Evaluation of the efficacy of pulsed electromagnetic field in the management of patients with diabetic polyneuropathy.
Graak V, Chaudhary S, Bal BS, Sandhu JS.
Int J Diabetes Dev Ctries. 2009 Apr;29(2):56-61. doi: 10.4103/0973-3930.53121.

Another 10 Hz rTMS study->>> Pain Med. 2009 Jul-Aug;10(5):840-9. Epub 2009 Jul 6.
A pilot study investigating the effects of fast left prefrontal rTMS on chronic neuropathic pain.
Borckardt JJ, Smith AR, Reeves ST, Madan A, Shelley N, Branham R, Nahas Z, George MS.
Department of Psychiatry, Medical University of South Carolina, Charleston, South Carolina 29425, USA.

Int J Diabetes Dev Ctries. 2009 Apr;29(2):56-61. in this study hundreds of hertz worked; but not healthy for your neuro system!
Graak V, Chaudhary S, Bal BS, Sandhu JS.
Department of Sports Medicine and Physiotherapy, Guru Nanak Dev University, Amritsar, Punjab, India.

Neurorehabil Neural Repair. 2004 Mar;18(1):42-6.
Pulsed magnetic field therapy in refractory neuropathic pain secondary to peripheral neuropathy.
Weintraub MI, Cole SP.
New York Medical College, Briarcliff Manor, New York 10510, USA.
CONTEXT: Neuropathic pain (NP) from peripheral neuropathy (PN) arises from ectopic firing of unmyelinated C-fibers with accumulation of sodium and calcium channels. Because pulsed electromagnetic fields (PEMF) safely induce extremely low frequency (ELF) quasirectangular currents that can depolarize, repolarize, and hyperpolarize neurons, it was hypothesized that directing this energy into the sole of one foot could potentially modulate neuropathic pain.
OBJECTIVE: To determine if 9 consecutive 1-h treatments in physician’s office (excluding weekends) of a pulsed signal therapy can reduce NP scores in refractory feet with PN.
DESIGN/SETTING/PATIENTS: 24 consecutive patients with refractory and symptomatic PN from diabetes, chronic inflammatory demyelinating polyneuropathy (CIDP), pernicious anemia, mercury poisoning, paraneoplastic syndrome, tarsal tunnel, and idiopathic sensory neuropathy were enrolled in this nonplacebo pilot study. The most symptomatic foot received therapy. Primary endpoints were comparison of VAS scores at the end of 9 days and the end of 30 days follow-up compared to baseline pain scores. Additionally, Patients’ Global Impression of Change (PGIC) questionnaire was tabulated describing response to treatment. Subgroup analysis of nerve conduction scores, quantified sensory testing (QST), and serial examination changes were also tabulated. Subgroup classification of pain (Serlin) was utilized to determine if there were disproportionate responses.
INTERVENTION: Noninvasive pulsed signal therapy generates a unidirectional quasirectangular waveform with strength about 20 gauss and a frequency about 30 Hz into the soles of the feet for 9 consecutive 1-h treatments (excluding weekends). The most symptomatic foot of each patient was treated.
RESULTS: All 24 feet completed 9 days of treatment. 15/24 completed follow-up (62%) with mean pain scores decreasing 21% from baseline to end of treatment (P=0.19) but with 49% reduction of pain scores from baseline to end of follow-up (P<0.01). Of this group, self-reported PGIC was improved 67% (n=10) and no change was 33% (n=5). An intent-to-treat analysis based on all 24 feet demonstrated a 19% reduction in pain scores from baseline to end of treatment (P=0.10) and a 37% decrease from baseline to end of follow-up (P<0.01). Subgroup analysis revealed 5 patients with mild pain with nonsignificant reduction at end of follow-up. Of the 19 feet with moderate to severe pain, there was a 28% reduction from baseline to end of treatment (P<0.05) and a 39% decrease from baseline to end of follow-up (P<0.01). Benefit was better in those patients with axonal changes and advanced CPT baseline scores. The clinical examination did not change. There were no adverse events or safety issues.
CONCLUSIONS: These pilot data demonstrate that directing PEMF to refractory feet can provide unexpected short term analgesic effects in more than 50% of individuals. The role of placebo is not known and was not tested. The precise mechanism is unclear yet suggests that severe and advanced cases are more magnetically sensitive. Future studies are needed with randomized placebo-controlled design and longer treatment periods.

Neurosci Behav Physiol. 2003 Oct;33(8):745-52.
The use of pulsed electromagnetic fields in treatment of patients with diabetic polyneuropathy.
Musaev AV, Guseinova SG, Imamverdieva SS.
Science Research Institute of Medical Rehabilitation, Baku, Azerbaidzhan.
Clinical and electroneuromyographic studies were performed in 121 patients with diabetic polyneuropathy (DPN) before and after courses of treatment with pulsed electromagnetic fields with complex modulation (PEMF-CM) at different frequencies (100 and 10 Hz). Testing of patients using the TSS and NIS LL scales demonstrated a correlation between the severity and frequency of the main subjective and objective effects of disease and the stage of DPN. The severity of changes in the segmental-peripheral neuromotor apparatus–decreases in muscle bioelectrical activity, the impulse conduction rate along efferent fibers of peripheral nerves, and the amplitude of the maximum M response–depended on the stage of DPN and the duration of diabetes mellitus. The earliest and most significant electroneuromyographic signs of DPN were found to be decreases in the amplitude of the H reflex and the Hmax/Mmax ratio in the muscles of the lower leg. Application of PEMF-CM facilitated regression of the main clinical symptoms of DPN, improved the conductive function of peripheral nerves, improved the state of la afferents, and improved the reflex excitability of functionally diverse motoneurons in the spinal cord. PEMF-CM at 10 Hz was found to have therapeutic efficacy, especially in the initial stages of DPN and in patients with diabetes mellitus for up to 10 years.

Fiziol Zh. 2003;49(2):85-90.
Use of low-power electromagnetic therapy in diabetic polyneuropathy [Article in Ukrainian]
Chebotar’ova LL, Chebotar’ov HIe.
The clinical-electroneuromyography investigations were performed for objective evaluation of low-power electromagnetic therapy effectiveness in 12 patients with diabetic polyneuropaties. It is established that combination of low-power electromagnetic therapy using “ANET-UHF”, “ANET-SHF” apparatus (Ukraine) and low-power variable magnetic field using AMT apparatus (Ukraine) give the stable positive effects. The positive changes were confirmed by following: the decrease of neurological deficit and required insulin daily dose, nerve conduction velocity increase, increase of the muscle compound action potentials (muscle power) and peripheral outflow in some patients.

Zh Nevrol Psikhiatr Im S S Korsakova. 2002;102(12):17-24.
Application of impulse complex modulated electromagnetic fields in management of patients with diabetic polyneuropathy
Musaev AV, Guseinova SG, Imamverdieva SS. [Article in Russian]
One hundred and twenty-one patients with diabetic polyneuropathy (DP) underwent a clinical and electroneuromyographic investigation before and after treatment with impulse complex modulated electromagnetic fields (ICM EMF) of varying frequency (100 and 10 Hz). Based on TSS and NIS LL scale tests, a correlation between the progression and occurrence of the basic subjective and objective signs of the disease and a DP stage was revealed. The alterations of segmental and peripheral neuromotor system manifesting in reduction of muscular bioelectrical activity, impulse conduction velocities in efferent fibers of peripheral nerves and maximal M-response amplitude were found to be related to DP stage and diabetes mellitus duration. A decrease of H-reflex amplitude and Hmax/Mmax ratio measured in crural muscles proved to be the earliest and most significant electroneuromyographic DP trait. ICM EMF application promotes a regression of DP basic clinical symptoms, an improvement of conduction function of peripheral nerves and 1a afferents state as well as a reflex excitability of functionally different spinal motoneurons. Therapeutic efficacy of a 10 Hz ICM EMF, particularly for DP primary stages and diabetes mellitus up to 10-year duration, was proved.

Neurophysiol Clin. 2001 Aug;31(4):247-52
Interventional neurophysiology for pain control: duration of pain relief following repetitive transcranial magnetic stimulation of the motor cortex.
Lefaucheur JP, Drouot X, Nguyen JP.
Service de physiologie-explorations fonctionnelles, hopital Henri-Mondor, Inserm U421, faculte de medecine, 94010 Creteil, France.
The chronic electrical stimulation of a motor cortical area corresponding to a painful region of the body, by means of surgically-implanted epidural electrodes is a validated therapeutical strategy to control medication-resistant neurogenic pain. Repetitive transcranial magnetic stimulation (rTMS) permits to stimulate non-invasively and precisely the motor cortex. We applied a 20-min session of rTMS of the motor cortex at 10 Hz using a ‘real’ or a ‘sham’ coil in a series of 14 patients with intractable pain due to thalamic stroke or trigeminal neuropathy. We studied the effects of rTMS on pain level assessed on a 0-10 visual analogue scale from day 1 to day 12 following the rTMS session. A significant pain decrease was observed up to 8 days after the ‘real’ rTMS session. This study shows that a transient pain relief can be induced in patients suffering from chronic neurogenic pain during about the week that follows a 20-min session of 10 Hz-rTMS applied over the motor cortex.